PC-07 Clinical evaluation of three commercial PCR assays for the - - PowerPoint PPT Presentation

1

Clinical evaluation of three commercial PCR assays for the detection of macrolide resistance of Mycoplasma genitalium

Chloé Le Roy1, Cécile Bébéar1-2, Sabine Pereyre1-2

• 1Univ. Bordeaux, INRA, USC EA 3671 Mycoplasmal and Chlamydial Infections in Humans,

2Reference National Center of bacterial STI, Bordeaux, France.

Bacteriology Department, Bordeaux University Hospital, Bordeaux, France.

➢ Clinical specimens : Prospective study between August 1st and December 31st 2018 at the National Reference Center for bacterial STI (Bordeaux, France) ➢ DNA extraction : MagNAPure 96TM instrument

(Roche Diagnostics).

➢ Detection : LightCycler 480 II instrument

(Roche Diagnostics).

PC-07

2

➢ Agreement of M. genitalium detection with the in-house real-time PCR assay1 on 195 M. genitalium positive specimens. ➢ Clinical performance of macrolide resistance detection on 154 M. genitalium-positive specimens.

CI: confidence interval; IC: Internal control. CI: confidence interval; WT: wild-type.

RESULTS

PC-07

1Jensen et al. J. Clin. Microbiol. 2004.

3

➢ The launch of three sensitive and specific commercial kits for the detection of M. genitalium and macrolide resistance will be useful to guide the choice of therapy. ➢ The three kits do not discern between absence of mutation and absence of 23S rRNA gene amplification, leading to a risk of false macrolide susceptible results when the 23S rRNA gene is not amplified. ➢ Cost and handling of commercial kits Le Roy C., Bébéar C. and Pereyre S. J Clin Microbiol. Clinical evaluation of three commercial PCR assays for the detection of macrolide resistance in Mycoplasma genitalium.

• 2019. in press.

PC-07

CONCLUSIONS